Gene · 51366
UBR5: ubiquitin protein ligase E3 component n-recognin 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. UBR5: ubiquitin protein ligase E3 component n-recognin 5. Genes, record 51366. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/51366
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95071 | E3 ubiquitin-protein ligase UBR5 | 2,799 | 11 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026507518 A | 2026-03-04 | 153 | O95071 | Espacenet |
| EP 4665771 A1 | 2025-12-24 | 153 | O95071 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 18096 | O95071 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 18096 | O95071 | Espacenet |
| JP 2022141755 A | 2022-09-29 | 195 | O95071 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 94641 | O95071 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 197612 | O95071 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 2744 | O95071 | Espacenet |
| US 10302646 B2 | 2019-05-28 | 117 | O95071 | Espacenet |
| JP 2019033757 A | 2019-03-07 | 24895 | O95071 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,184
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | UBR5 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 13 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 5 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 4 | 2025 |
| R01DK039520 | New Mechanisms and Functions of the Pro/N Degron and Arg/N-Degron Pathways | 4 | 2025 |
| R01GM031530 | Superchanneling, Regulation of Caspases, and Site-Specific Control of RNA | 4 | 2025 |
| P20GM121316 | Nebraska Center for Molecular Target Discovery and Development | 3 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,184Source NIH's project files
See all 1,184 nih grantsPapers1,630
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| UBR5-KDM5A axis rewires redox metabolism to confer cisplatin resistance in triple-negative breast cancer via the cAMP-PKA-SIRT3 cascade. | Drug Resist Updat | 2026 | 42809895 | PubTator, text mining | PubMed |
| JNK acts as a molecular brake of the CDC73 positive feedback loop to modulate osteosarcoma malignant progression via UBR5. | Oncogene | 2026 | 42749759 | PubTator, text mining | PubMed |
| Dynamic Prediction of Survival Outcomes in Multiple Myeloma. | Cancers (Basel) | 2026 | 42738384 | PubTator, text mining | PubMed |
| Correction to: UBR-box containing protein, UBR5, is overexpressed in human lung adenocarcinoma and is a potential therapeutic target. | BMC Cancer | 2026 | 42717320 | PubTator, text mining | PubMed |
| UV-B enhances hyperaccumulation of α- and β-carotene in marigold petals. | Plant Physiol Biochem | 2026 | 42526340 | PubTator, text mining | PubMed |
| Mechanistic and functional study of lncRNA SNHG3/miR-128-3p/UBR5 axis in neuroinflammation in Alzheimer's disease. | J Gerontol A Biol Sci Med Sci | 2026 | 42502987 | PubTator, text mining | PubMed |
| Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome system. | Cell Death Differ | 2026 | 42472879 | PubTator, text mining | PubMed |
| Network pharmacology combined with molecular docking to investigate the potential role of curcumin targeting TGR5 to modulate the GLP-1 pathway in T2DM with obesity. | Pak J Pharm Sci | 2026 | 42433074 | PubTator, text mining | PubMed |
| Distinct Proteasomal Pathways Drive Oncogenic PPM1D Activation. | bioRxiv | 2026 | 42282570 | PubTator, text mining | PubMed |
| Defining a Novel 8q22.3 Microdeletion Syndrome Caused by UBR5 Haploinsufficiency. | Pediatr Neurol | 2026 | 42263457 | PubTator, text mining | PubMed |
1 to 10 of 1,630
See all 1,630 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/51366
GET https://conductscience.org/api/genes/v1/51366/patents?page=2